- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Lutera is latest birth control recall
Actavis is voluntarily recalling more than half a million boxes of Lutera birth control pills because of packaging problems.
Actavis is voluntarily recalling more than half a million boxes of Lutera birth control pills because of packaging problems.
Related: FDA, PatientsLikeMe partner on drug safety data
Allergan’s Actavis is recalling 26 lots, or 511,283 boxes of Lutera because the packaging inserts are out-dated, according to the FDA enforcement report. Patheon manufactured the pills.
While there is no danger to consumers, according to the FDA, 2 other birth control medications have been recalled so far this year. In April, Johnson & Johnson's Janssen recalled a single lot of Ortho-Cept tablets in Canada because of the potential that the potency of the two active ingredients may not meet specifications and be effective.
Related: Pharma needs to be more upfront about drug rejections
Also this spring, Shoppers Drug Mart in Canada said that it mistakenly released some expired packages of Pfizer's Alesse 21 pills. The expired pills might not meet specifications and could result in unwanted pregnancies, according to Health Canada.
Read next: Gilead sues to stop Actavis' generic bid for Letairis
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
